and often with S100 protein, and contain neurofilaments. Electron microscopy shows a few cell processes and occasional neurosecretory granules. This contrasts with the more 'classical' Ewing's tumour which fails to react with any of the 'neural' antibodies and electron microscopy shows cells having a bland primitive appearance containing only a few mitochondria, some lipid and some glycogen. There is no neural differentiation. Between these two extremes there are tumours described as 'atypical' Ewing's tumour which display some reactivity with NSE but not with other 'neural' antibodies. Electron microscopy shows atypical features such as cell processes but there are not neurosecretory granules. The so-called 'Askin' tumour is similar but has some definite neural differentiation. Consistent rearrangements to chromosome 11 at bands q23-q24 have been reported in a variety of malignancies. The translocation t(4; 1 1)(q21 ;q23), first reported by Van den Berghe et al. in (1979) , is associated with infantile acute lymphoblastic leukaemia while the translocations t(9; I 1) (p22;q23) and t(I 1; 19)(q23;pl 3) have been observed in cases of acute monocytic leukaemia. The translocation t(l 1;22)(q24;q 12) is exhibited in 85% of Ewing's sarcoma and is also seen in neuroepithelioma and Askin tumours. Although currently there is little information on the molecular effects of these alterations, it has been established that the c-ets-J oncogene on chromosome 11 lies distal to the position of the t(4;11) breakpoint, the t(9;11) breakpoint and proximal to the t (I 1;22) In 1978 a protocol for patients with Ewing's sarcoma (ES) of bone was designed to evaluate (1) the initial response of previously untreated tumour to cyclophosphamide (Cy) and adriamycin (Adr) induction chemotherapy, (2) local control of primary tumours with chemotherapy plus no radiotherapy (RT) (resected lesions) delayed low-dose (30-50 Gy) limited port RT (partial clinical responders) and (3) the overall disease control interval to relatively non-aggressive chemotherapy given for 10-12 months duration.
Eighty patients entered this study, 59 with localised disease and 21 with metastatic tumour. The age range was from 2 years 10 months to 21 years 11 months (median 15 years).
All patients received Cy (150 mg m-2 day-' p.o. x 7) and Adr (35 mg m-2 on day 8) starting on days 1, 15, 29, 50 and 71. All patients were then evaluated for response to induction therapy. Continuation therapy consisted of vincristine (1.5mgm-2 every week x 11, maximum 2mgdose-') and dactinomycin (1.5 mg m-2 every 2 weeks x 6, maximum 2 mg dose-') followed by a further six cycles of Cy-Adr given at 3-week intervals. Those with metastatic disease then received a further 11 weeks of vincristine and dactinomycin as shown above.
RT was delayed until induction therapy was completed and when delivered was given to limited ports based on post-induction residual lesions. Patients with pulmonary metastases at diagnosis who achieved complete responses with Cy-Adr induction did not receive pulmonary RT. The dose of RT delivered depended on response to induction chemotherapy and surgical resectability of residual lesions.
Of the 21 patients with metastatic tumour, only two failed to achieve a good response to chemotherapy induction. The 5-year disease-free survival (DFS) is 38% and survival (S) is 52% with one relapse occurring beyond 5 years.
Of the 59 patients with localised disease, only four failed to achieve an excellent response to induction chemotherapy. The overall 5-year DFS and S for all 59 patients is 61% and 78% respectively.
The size of the primary lesion at diagnosis was a significant factor in whether or not local control and therefore DFS was maintained. Of 29 patients with lesions less than 8 cm in diameter at diagnosis 27 achieved CR, 21 are disease-free and 25 survive. Eight patients received no RT, 18 low dose RT (three local and two metastatic relapses) and one standard dose RT (one metastatic relapse). Of the 27 achieving CR, three relapsed in the local site and three in a metastatic site for a 5-year DFS of 72% and a S of 83%.
Of the 30 patients with lesions greater than 8 cm at diagnosis, 28 achieved CR, 15 remain free of disease and 20 survive. Six patients received no local RT (two metastatic relapses), 16 received low dose RT (five local, four local plus metastatic relapses), and six received standard dose RT (three local relapses). Of the 28 achieving CR, eight relapsed in the local site, four in the local plus metastatic sites, and two in a metastatic site only for a 5-year DFS of 53% and S of 68%.
The difference between the local control rate in small lesions versus large lesions is significantly different (P = 0.025). Local recurrences occurred in the centre of the radiation port in 14 of 15 cases indicating that the small ports of RT delivered did not contribute to the loss of local control.
Results of this study suggest: (1) low doses of Cy-Adr are very effective induction therapy in previously untreated patients with ES; (2) relatively non-aggressive chemotherapy delivered for 10 months results in excellent control of micrometastatic tumour in that only five of 55 responding patients with localised disease relapsed in an isolated metastatic site; (3) in small lesions, therapy as delivered in this study provides disease control as good as or better than that reported with more aggressive therapy, and dose so with minimal toxicity; (4) in larger lesions, therapy as delivered is comparable to other reported studies but as with other studies control is not adequate; (5) markedly limiting the port of RT does not result in 'marginal miss' recurrences and hopefully will decrease long-term growth problems in survivors. Patients received vincristine 2 mg m-2, adriamycin 50 mg m-2, and cyclophosphamide 1,000 mg m-2 on day 1.
On days 8 and 15 they received vincristine 2 mg m-2, on days 22, 29, 36 and 43, vincristine 2 mg m-2 and cyclophosphamide 400 mg m-2 were given. Radiotherapy was given on days 15-43. On day 64, vincristine 2 mg m2, adriamycin 50 mg m2 and cyclophosphamide 600 mg m2 (VAdC) was given, and on day 85 vincristine 2mgm-2, actinomycin D 1.4 mg m2, cyclophosphamide 600 mg m-2 (VAC) was given. Alternating VAdC and VAC every three weeks was given for 2 years. Actinomycin D was substituted for adriamycin after a total accumulated adriamycin dose of 300 mg m2. If a good clinical response to VAdC was obtained, a second or third course could be given before radiotherapy.
The radiotherapy progamme was given as follows. In the long bones, the initial fields included the whole bone at 45 Gy + 1,200 Gy boost to the tumour. In the spine, the field included vertebrae above and below the tumour -a dose of 40 Gy was given. In the ribs, the field included the vertebral body to a dose of 25 Gy. In the pelvis, the field included at least the hemipelvis and whole sacrum -30 Gy + 15 Gy boost to tumour. Surgery could be undertaken at the discretion of the clinician.
Of the 152 patients entered into the first trial, 142 were analysable. Of these, 22 had metastases at diagnosis, and 120 did not. In the metastatic group, two had proximal disease and both died; 14 had distal disease, and 12 of these died; five had axial disease, of whom one survives. In the patients free of metastases, 27 had proximal disease and 12 died; 31 had distal disease and 13 died; 62 had axial disease and 32 died.
Thus the survival for patients with no metastases was 41 %, but for those with metastases 11 %. Survival was better for girls than boys, for those under the age of 15, and for those having proximal and distal primary sites. Poor survival for axial tumours was due not only to the increased rate of local recurrence, but also to metastatic disease. Surgery was increasingly used during the period of study, and improved local control of disease and survival.
The second protocol followed this study and was a singlearmed, non-randomised study in Ewing's tumour of bone utilising vincristine, adriamycin, actinomycin D and ifosfamide, and either surgery and/or radiotherapy as a definitive treatment for the primary tumour. The aims were to achieve the best possible cure rate for patients with Ewing's sarcoma, to determine whether it was possible to grade histological response of the primary tumour and relate this to outcome, to assess the feasibility of surgery for all cases, to determine whether the dose of radiotherapy can be reduced in those patients who have surgery, and to assess the response rate and toxicity of IVAD/IVA chemotherapy. Eligible patients included all those who had biopsy-proven Ewing's sarcoma of bone, those who were 30 years of age or younger, who had had no prior local therapy other than biopsy, and patients with metastases.
Patients started therapy with 'IVAD3' at 3-weekly intervals. IVAD3 was: ifosfamide 3 mg m-2 daily for 3 days; mesna 3 mg m-2 daily for 3.5 days; vincristine 2 mg m-2 (2 mg max.) on day 1 only; adriamycin 20 mg m-2 daily for 3 days.
At the end of this therapy they were considered for surgery. Those who had had no surgery or biopsy only were treated with radiotherapy and vincristine 2 mg m-2 (max. 2 mg) and cyclophosphamide 300 mg m2. Those who had surgery and a complete resection had no radiotherapy. Those who had had an incomplete resection had radiotherapy and vincristine and cyclophosphamide in the doses given above.
All patients subsequently received 'IVAD2' for three courses at 3-weekly intervals, and finally IVA at 2-weekly intervals until the 52nd week of the programme. IVAD2 was: ifosfamide 3 mg m-2 daily for 2 days; mesna 3 mg m-2 daily for 2.5 days; vincristine 2 mg m-2 (max. 2 mg) on day 1 only; adriamycin 30 mg m-2 daily for 2 days. IVA was as above, but actinomycin D 1.5 mg m-2 on day 1 only instead of adriamycin.
To date 82 patients have been entered into this study. The features of the cohort were very similar to those of the first, except that approximately double the number of the patients in the latest study had metastases on presentation compared with the first study. This may, however, have represented better staging techniques. With respect to treatment, 26% of patients in the first study had surgery, while 80% did so in, the second. The acute toxicity of the second programme is severe, but is tolerable and no serious cardiotoxicity has been seen. The majority of patients who had comprehensive renal assessment at the end of treatment have evidence of glomerular and/or tubular toxicity. It is too early yet to give survival data. Between 1978 and 1982, 96 children with localised Ewing's sarcoma were treated wity cyclosphosphamide containing initial chemotherapy, radiotherapy maintenance chemotherapy. At 3 years, the disease-free survival was 52% and remains stable 3 years later.
In the subsequent study (1984) (1985) (1986) (1987) DI-D2-D3) alternating every 3 weeks with three cycles of IVAd (IFO 3 g m 2 Dl-D2, vincristine 1.5 mg m 2 D1, adriamycin 60 mg m-2 DI, in pulse). Radical surgery was then considered for each case. Radiotherapy dose had to be decided according to the surgery: 40 Gy in patients who had complete surgical resection of their tumour, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] (median 11.5 years). Fifty-two per cent of the tumours were located on axial bones, and 48% on limbs. Thirty-nine patients could undergo surgical resection of their tumour with conservative procedure in 34 cases. By May 1989, 31 failures had been observed: one initial progression, 14 local relapses, and 16 metastases. So the disease-free survival at 36 months is only 50% and quite similar to the rate observed in the first study.
In the ifosfamide study, we observed congested heart failure in three patients, occurring 6-8 weeks after the end of therapy and cumulative doses of adriamycin ranging from 420 to 480 mg m 2. Two of these patients died, one is alive after heart transplantation. (In the cyclophosphamide study, a single case of moderate cardiac failure was observed, after cumulative dose 240 mg m-2 of adriamycin.) Beside this acute major toxicity, in the ifosfamide study, seven patients had significant echocardiographic abnormalities. The problem with these studies has been that it is not possible to say with certainty which chemotherapy regimens are the most effective, and which strategies should be adopted for improving local recurrence rate. Randomised studies are necessary to make some assessment of these problems.
The difficulty in Ewing's sarcoma is that the disease is rare and different strategies may be needed for patients who are already doing well with current treatment policies, compared with those who are at risk of failure. It seems unlikely that improvement in survival of more than 15% is to be expected by intensification, or alteration, of treatment, but such improvements are well worthwhile and studies need to be designed in order to detect them. If we take overall survival of 60% as being representative of Ewing's sarcoma in general, to improve this survival to 70% will require a randomised trial of 562 patients (80% power, 5% significance); an improvement to 80% will require 137 patients to be randomised, and 90% will require 61 patients. An improvement of survival from 65% to 80% would require 226 patients to be randomised. Randomised trials containing 250-300 patients are not impossible in Ewing's sarcoma, but would inescapably mean a high degree of national and international co-operation. Nonetheless, large groups such as the MRC/UKCCSG admit 50-60 patients into studies each year, and it would only require two or three such groups to join to be able to make important contributions to management.
What questions might realistically be posed in intergroup studies of this kind?
1. In good prognosis patients (a term which would require definition) it is important to assess whether the chemotherapy introduced by the St Jude's group, which is relatively nontoxic and of low intensity, is really the equivalent of, or better than the more intensive programmes currently used by the West German or English groups. This can only be assessed in a randomised setting, and the result would be of practical importance for many of our patients.
2. For the poor prognosis patients, studies can be set up in which attempts to assess local control may be made. Such trials might, in unresectable lesions, assess radiotherapy given concomitantly with chemotherapy or sequentially after induction chemotherapy. Such an approach could also be tried in metastatic cases where surgical resection is considered less important. Similarly, in resectable lesions, an assessment could be made of whether radiotherapy is better given before or after surgery. In these patients an alternative study might be to determine whether the dose of radiation required to achieve local control needs to be as high as 50 Gy or can be reduced following successful resection. These questions of dosage are of importance both in functional results and in terms of second cancers in irradiated bone, which is a serious long term problem for bone radiation in Ewing's sarcoma.
Studies on local control rates would be best done in a randomised phase II setting, and far fewer patients would be needed than are required to assess survival. Such studies are eminently feasible among groups working in collaboration, but it would probably be necessary to restrict the collaborators to five or six major centres in order to ensure quality control of surgery and radiation. These studies are likely to generate data from which future randomised trials can be planned.
3. Patients with metastases, particularly in bones, have very bad prognosis and phase II studies can be designed which allow us to ask questions concerning dose intensity of chemotherapy. Such studies might involve the use of haemopoietic growth factors or late intensification schemes using high-dose chemotherapy and autologous bone marrow transplantation.
Collaborative intergroup studies of this kind also permit co-operation between histologists in defining the importance of the neuroectodermal phenotype and its relationship to prognosis. It will also allow pathologists to agree on scoring systems for necrosis following chemotherapy. Other collaborative studies would allow comparison of CT scan estimation of tumour volume and its relationship to prognosis and multivariate analysis of prognostic variables in large data sets. These latter aspects of collaboration could proceed even without collaborative clinical studies, but the great advantage of clinical programmes, particularly when randomised, is that they generate close working relationships and enthusiasm and excitement about the outcome of the studies.
Summary and conclusions
C.R. Pinkerton & J.S. Malpas
The histogenesis of Ewing's sarcoma still represents something of a mystery, but it seems likely that a tumour of common origin presents either in an undifferentiated form as a classical Ewing's sarcoma, or with varying degrees of neural differentiation, the most differentiated being the classical primitive neuroectodermal tumour PNET. Immunochemical and cytogenetic studies may help to elucidate their relationship. International co-operation between histologists to provide adequate numbers to be able to produce definitive statements are now necessary.
It is essential that all modern investigative techniques be used in assessing and staging Ewing's sarcoma, as it is evident that the prognosis for metastatic disease compared with earlier stages is very much worse. Although new methods such as MRI have not made a very significant contribution to this problem, MRI does give additional information, helping to delineate the primary tumour and assess the amount of bone-marrow disease.
The large national studies on the treatment of Ewing's sarcoma which were reported were largely observational. The rarity of the tumour precludes randomised trials. The only possibility of answering the numerous questions that these studies have now raised will be through co-operative trials, and it is thought that this group should endeavour to initiate them.
